FIGHT THE PIRATE OF THE SIGHT

Travonorm Plus
Travoprost 0.004%
Timolol 0.5%
Product Information

Drug Class

• Anti-glaucomatous eye drops related to the combination group of Prostaglandins Analogues group & Beta blockers group..

Product Description

➢ Active Ingredient:
• Travoprost 40ug/ml = 0.004%
• Timolol 5mg=0.5%

➢ Preservative:
• 0.015% Benzalkonium Chloride

Clinical Studies
Travonorm Plus provides up to 38% reduction in IOP over 12 months

Powerful & Rapid reduction in IOP from baseline.
Sustained action with uniform IOP for 1 year.

Travonorm Plus shows better IOP control than Latanoprost/Timolol fixed combination

Target IOP Satisfaction Rate

<table>
<thead>
<tr>
<th>IOP (mm Hg)</th>
<th>Latanoprost/ Timolol FC</th>
<th>Travoprost/ Timolol FC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>25.8</td>
<td>25.8</td>
</tr>
<tr>
<td>Travoprost / Timolol FC (after 24 hours)</td>
<td>17</td>
<td>20.3</td>
</tr>
<tr>
<td>Latanoprost / Timolol FC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

n=207
n=316
Travonorm Plus delivers additional reduction when switching from Prostaglandins analogues

43 patients received Travoprost  
18 patients received Bimatoprost  
4 patients received Latanoprost

Travonorm Plus Evening Dose is more preferred than Morning Dose

Also results in a lower 24-hour IOP fluctuation:
- Evening dose: 3.8 mmHg
- Morning dose: 5.1 mmHg

Time Interval (after 8 weeks)
Travonorm Plus, Travoprost, belongs to Prostaglandin analogue group with Timolol, a non-selective beta-adrenergic blocking agent

1. Achieves up to 38% reduction in the IOP which considered one of the highest percentage of reduction in IOP among all anti-glaucoma groups.
2. Minimizes the diurnal variation of IOP so decreases the risk of visual field loss.
3. Decrease risk of side effects

- The only FP full agonist, effective reduction with tolerable hyperemia.
- Dual mechanism of action providing powerful effective reduction of IOP, the ideal shifting drug from PG for those who need 3 to 4 mmHg additional reduction
- No need for refrigeration.
- Lower incidence of hyperemia, improving patient’s compliance
- Lower preservative dose, improves patient’s tolerability
- Once daily in the evening for better patient compliance.